>
Immuron logo

IMC - Immuron Share Price

A$0.17 0.0  0.0%

Last Trade - 10/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £21.6m
Enterprise Value £6.85m
Revenue £551k
Position in Universe 1231st / 1907
Bullish
Bearish
Unlock IMC Revenue
Momentum
Relative Strength (%)
1m -17.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -82.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.12 4.00 2.98 3.69 2.39 2.52 +17.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ImmuronLtd revenues decreased 99% to A$20K. Net loss increasedfrom A$1.5M to A$5.7M. Revenues reflect Australia segmentdecrease of 98% to A$17K, Other segment decrease of 90% toA$22K. Higher net loss reflects Unallocated Corporatesegment loss increase from A$1.6M to A$4.8M, HyperImmuneProducts segment loss totaling A$163K vs. income of A$550K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IMC Revenue Unlock IMC Revenue

Net Income

IMC Net Income Unlock IMC Revenue

Normalised EPS

IMC Normalised EPS Unlock IMC Revenue

PE Ratio Range

IMC PE Ratio Range Unlock IMC Revenue

Dividend Yield Range

IMC Dividend Yield Range Unlock IMC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IMC EPS Forecasts Unlock IMC Revenue
Profile Summary

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated January 13, 1994
Public Since April 30, 1999
No. of Shareholders: n/a
No. of Employees: 25
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 226,837,506
Free Float (0.0%)
Eligible for
ISAs
SIPPs
IMC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IMC
Upcoming Events for IMC
Friday 29th October, 2021 Estimate
Immuron Ltd Annual Shareholders Meeting
Frequently Asked Questions for Immuron
What is the Immuron share price?

As of 10/05/21, shares in Immuron are trading at A$0.17, giving the company a market capitalisation of £21.6m. This share price information is delayed by 15 minutes.

How has the Immuron share price performed this year?

Shares in Immuron are currently trading at A$0.17 and the price has moved by 0.107k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Immuron price has moved by 55.33% over the past year.

What are the analyst and broker recommendations for Immuron?

Of the analysts with advisory recommendations for Immuron, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Immuron is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Immuron next release its financial results?

Immuron is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Immuron dividend yield?

Immuron does not currently pay a dividend.

Does Immuron pay a dividend?

Immuron does not currently pay a dividend.

When does Immuron next pay dividends?

Immuron does not currently pay a dividend.

How do I buy Immuron shares?

To buy shares in Immuron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Immuron?

Shares in Immuron are currently trading at A$0.17, giving the company a market capitalisation of £21.6m.

Where are Immuron shares listed? Where are Immuron shares listed?

Here are the trading details for Immuron:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: IMC
What kind of share is Immuron?

Based on an overall assessment of its quality, value and momentum, Immuron is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Immuron share price forecast 2021?

We were not able to load any forecast data for Immuron.

How can I tell whether the Immuron share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immuron. Over the past six months, the relative strength of its shares against the market has been -37.8%. At the current price of A$0.17, shares in Immuron are trading at -32.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Immuron PE Ratio?

We were not able to find PE ratio data for Immuron.

Who are the key directors of Immuron?

Immuron's management team is headed by:

Roger Aston - NEC
Daniel Pollock - NED
Phillip Hains - SEC
Stephen Anastasiou - NED
Peter Anastasiou - VCH
Jerry Kanellos - COO
Ravi Savarirayan - DRC
Who are the major shareholders of Immuron?

Here are the top five shareholders of Immuron based on the size of their shareholding:

Grandlodge Pty. Ltd. Corporation
Percentage owned: 4.59% (10.4m shares)
Authentics Australia Pty. Ltd. Corporation
Percentage owned: 3.3% (7.50m shares)
Hancock (Russell Kay) Individual Investor
Percentage owned: 1.32% (3.00m shares)
Insync Investments Pty Ltd Corporation
Percentage owned: 0.88% (2.00m shares)
Aston (Roger) Individual Investor
Percentage owned: 0.67% (1.52m shares)
Similar to IMC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.